Mytecirin-L (Liposomal Amphotericin Vials) 50mg

Mytecirin-L is a liposomal amphotericin B formulation in 50mg vials for antifungal therapy. This targeted delivery system enhances efficacy while reducing toxicity compared to conventional amphotericin. Ideal for systemic fungal infections and broad-spectrum antifungal coverage. Short-term use under medical supervision recommended.

Strength

50mg

Pack Size

Storage

Ambient

Manufacturer / TM Owner

Maya biotech Pvt Ltd.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Mytecirin-L is used for treating serious systemic fungal infections such as invasive aspergillosis, candidiasis, and cryptococcal meningitis. It may also be prescribed for patients unresponsive to conventional amphotericin B. This liposomal form is particularly useful in immunocompromised individuals. Always consult a healthcare provider for suitability.

Side Effects

Mytecirin-L works by binding to fungal cell membranes, disrupting their integrity and leading to cell death. Patients may notice improvement in symptoms like fever or lesions during treatment. The liposomal formulation is designed to concentrate in infected tissues while minimizing exposure to healthy cells.

Precautions & Warnings

Store Mytecirin-L at ambient temperature away from moisture and direct light. Protect vials from freezing and handle with care to avoid contamination. Use within the expiry date and discard any unused solution properly. Always follow healthcare provider instructions for administration and monitoring.

Avoid Interactions

Mytecirin-L may interact with other medications affecting kidney function or potassium levels. Caution is advised when used with nephrotoxic drugs or corticosteroids. Inform your doctor about all medications, including over-the-counter and herbal products. Regular monitoring of kidney function is recommended during treatment.

References

Frequently Asked Questions

Mytecirin-L is used to treat serious systemic fungal infections like aspergillosis and candidiasis.

Mytecirin-L is administered intravenously by a healthcare professional.

Mytecirin-L may be available for purchase through licensed pharmacies with a prescription.

Common side effects may include fever, chills, or infusion-related reactions.

Consult a healthcare provider before using Mytecirin-L if pregnant or breastfeeding.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.